SS-31 Dosing & Reconstitution Guide
Dosing Protocol
Route: Subcutaneous Frequency: Once daily Dose Range: 5–40 mg/day SC (Phase I tested 0.01–0.25 mg/kg); research protocols typically 10–50 mg Cycle Length: 4–12 weeks; clinical trials ran 12–28 weeks Timing: Any consistent time
Reconstitution
Vial Size: 30mg Water Volume: 3mL Concentration: 10mg/mL
Titration Schedule
Week 1: 10 mg daily Weeks 2+: 20–40 mg daily
Storage
Lyophilized: −20 °C (−4 °F) Reconstituted: 2–8 °C (35.6–46.4 °F) Shelf Life: 28 days
Injection Sites
Abdomen, Thigh
Safety & Contraindications
Safety: Generally well-tolerated in clinical trials at tested doses Common: injection site reactions (pain, redness) Mild headache, dizziness, and nausea reported
Contraindications: Pregnancy and breastfeeding (insufficient data); Severe renal impairment (limited pharmacokinetic data); Hypersensitivity to any component